Loring Wolcott & Coolidge Fiduciary Advisors LLP Blueprint Medicines Corp Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$10.9 Billion
Q4 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $1,979 - $2,435	-21 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$82.78 - $101.0 $1,738 - $2,121	21 New	21 $2,000

Others Institutions Holding BPMC

# of Institutions

379

Shares Held

61.6M

Call Options Held

1.6M

Put Options Held

1.41M

Vanguard Group Inc Valley Forge, PA

6.77M
Shares

$645 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$633 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.68M
Shares

$541 Million
0.06% of portfolio
State Street Corp Boston, MA

2.5M
Shares

$238 Million
0.01% of portfolio
William Blair Investment Management, LLC Chicago, IL

1.94M
Shares

$185 Million
0.44% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.69B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account